SCHEMBL1407437

SCHEMBL1407437

Cc1ccc(C(F)(F)F)cc1CCc1cccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2F)c1

nearest known ligand 0.66

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 13/20 0.66
NR1H3 Q13133 13/20 0.66
NR1I2 O75469 2/20 0.51
NR3C1 P04150 2/20 0.51
AR P10275 1/20 0.51
RXRA P19793 1/20 0.51
PTGER4 P35408 1/20 0.35
GRM2 Q14416 2/20 0.35
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CCR2 P41597 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
VNN1 O95497 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857489 0.94 NR1H2 (0.69) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407952 0.93 NR1H2 (0.68) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407474 0.93 NR1H2 (0.67) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408099 0.93 NR1H2 (0.67) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407644 0.93 NR1H2 (0.67) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408087 0.89 NR1H2 (0.74) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1414362 0.88 NR1H2 (0.70) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408166 0.88 NR1H2 (0.72) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407668 0.88 NR1H2 (0.75) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407908 0.87 NR1H2 (0.71) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.